Welcome to Entry Card of Lysosomal Enzymes


Details of RareLED ID Assay_1001
Primary information
GENEACP2
NUMBER OF ASSAY87
ASSAY IDs362077 412398 594200 594199 161366 151039 412225 161367 412399 412224 1135086 100365 44010 44009 654973 654972 598865 594198 594197 1128904 151040 412400 1167333 1167331 1135087 1135042 1071686 1071684 300021 300020 269828 262278 1242497 1206949 1206779 1182547 1166647 1166646 1060783 1060781 755757 725027 696430 696429 695217 687541 687540 652645 652644 607545 471135 459326 415734 415733 414658 414657 414655 414654 414645 414644 1343616 1291102 1291101 743307 686962 651700 403719 403718 300022 295178 1235086 1235081 1128909 1128908 1128907 1128906 1128905 696434 496601 454222 430760 430022 430021 430020 415735 1264449 2628
Assay Name1. Inhibition of human prostatic acid phosphatase,2. Inhibition of red kidney bean PAP at pH 6.2,3. Uncompetitive inhibition of red kidney bean PAP using para-nitrophenol as substrate at pH 4.9 preincubated for 10 mins by UV-visible spectrophotometry,4. Competitive inhibition of red kidney bean PAP using para-nitrophenol as substrate at pH 4.9 preincubated for 10 mins by UV-visible spectrophotometry,5. Compound was tested for its inhibitory activity against human prostatic acid phosphatase,6. Tested for 50% of inhibition of Osteoclastic acid phosphatase (OAP) activity, determined using dose-response curve,7. Activity of red kidney bean PAP at pH 6.2,8. Inhibition of human prostatic acid phosphatase was determined as inhibition of the hydrolysis of tyrosine phosphate,9. Activity of pig PAP at pH 4.9,10. Inhibition of human PAP,11. Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs in presence of 5 uM prednisolone by trypan blue exclusion assay,12. In Vitro evaluation for the antiproliferative activity by observing the growth inhibition of L1210 lymphoid leukemia cells in culture at 72 hour,13. In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL),14. In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL),15. Uncompetitive inhibition of pig PAP using para-nitrophenol as substrate at pH 4.9 preincubated for 10 mins by UV-visible spectrophotometry,16. Competitive inhibition of pig PAP using para-nitrophenol as substrate at pH 4.9 preincubated for 10 mins by UV-visible spectrophotometry,17. Antiresorptive activity in mouse RAW264.7 cells assessed as inhibition of RANKL-induced osteoclastogenesis after 4 days by TRAP assay,18. Uncompetitive inhibition of pig PAP using para-nitrophenol as substrate at pH 4.9 preincubated for 10 mins by UV-visible spectrophotometry,19. Competitive inhibition of pig PAP using para-nitrophenol as substrate at pH 4.9 preincubated for 10 mins by UV-visible spectrophotometry,20. Inhibition of red kidney beans purple acid phosphatase,21. Compound was tested for its inhibitory activity against Osteoclastic acid phosphatase,22. Inhibition of pig PAP at pH 4.9,23. Inhibition of chymotrypsin-like activity of proteasome in rat liver using Suc-Leu-Leu-Val-Tyr-MCA fluorogenic substrate,24. Inhibition of sRANKL-induced TRAP activity in mouse RAW264 cells by p-nitrophenolate release based TRAP assay,25. Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs in presence of 100 uM prednisolone by trypan blue exclusion assay,26. Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay,27. Antioxidant activity assessed as trolox equivalent of APPH-induced peroxyl radical scavenging activity at 1 uM measured every 2 mins by ORAC fluorescence assay,28. Antioxidant activity assessed as reduction of Cu2+ to Cu+ at 10 uM,29. Inhibition of human low molecular weight Protein-tyrosine phosphatase IF2,30. Inhibition of human low molecular weight Protein-tyrosine phosphatase IF1,31. Inhibition of HCPTPA,32. Inhibition of HCPTPA,33. Inhibition of phosphatase activity of human LMWPTP using pNPP as a substrate after 10 mins by spectrophotometer analysis,34. Inhibition of full length 6-His-N-terminal tagged human LMW-PTP expressed in Escherichia coli BL21 (DE3) cells assessed as pNP formation using pNPP as substrate incubated for 15 mins prior to substrate addition by plate reader analysis,35. Inhibition of LMWPTP (unknown origin) using pNPP as substrate at pH 7 at 25 degC by spectrophotometric analysis,36. Inhibition of LMWPTP (unknown origin),37. Inhibition of human LMW-PTP IF2 using p-nitrophenylphosphate as substrate by spectrophotometry,38. Inhibition of human LMW-PTP IF1 using p-nitrophenylphosphate as substrate by spectrophotometry,39. Inhibition of human recombinant LMW-PTP IF1 expressed in Escherichia coli TB1 using p-nitrophenylphosphate as substrate,40. Inhibition of human recombinant LMW-PTP IF2 expressed in Escherichia coli TB1 using p-nitrophenylphosphate as substrate,41. Inhibition of recombinant LMWPTP (unknown origin) using pNPP as substrate by spectrophotometric analysis,42. Inhibition of LMWPTP (unknown origin) expressed in Escherichia coli using pNPP substrate after 5 mins by spectrophotometric analysis,43. Inhibition of human LMW-PTPase isoform 2,44. Inhibition of human LMW-PTPase isoform 1,45. Inhibition of LMPTP-A expressed in Escherichia coli BL21 using pNPP substrate,46. Inhibition of human recombinant LMW-PTP2 expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate after 1 hr,47. Inhibition of human recombinant LMW-PTP1 expressed in Escherichia coli TB1 using p-nitrophenyl phosphate as substrate after 1 hr,48. Competitive inhibition of GST-tagged human recombinant LMW-PTP IF2 expressed in Escherichia coli TB1 using p-nitrophenylphosphate as substrate by Line-Weaver Burk plot,49. Competitive inhibition of GST-tagged human recombinant LMW-PTP IF1 expressed in Escherichia coli TB1 using p-nitrophenylphosphate as substrate by Line-Weaver Burk plot,50. Inhibition of LMW-PTP,51. Inhibition of human HCPTPA,52. Inhibition of LMWPTP expressed in Escherichia coli assessed as inhibition of p-nitrophenyl phosphate hydrolysis at pH 7 by spectrophotometry,53. Inhibition of GST-tagged human LMW PTP1B IF1 isoform,54. Inhibition of GST-tagged human LMW PTP1B IF1 isoform,55. Inhibition of human cloned LMW-PTP isoform 2 expressed in Escherichia coli TB1 by competitive inhibition assay,56. Inhibition of human cloned LMW-PTP isoform 1 expressed in Escherichia coli TB1 by competitive inhibition assay,57. Inhibition of human cloned LMW-PTP isoform 2 expressed in Escherichia coli TB1 by mixed type inhibition assay,58. Inhibition of human cloned LMW-PTP isoform 1 expressed in Escherichia coli TB1 by mixed type inhibition assay,59. Inhibition of human cloned LMW-PTP isoform 2 expressed in Escherichia coli TB1,60. Inhibition of human cloned LMW-PTP isoform 1 expressed in Escherichia coli TB1,61. PTP pNPP Assay: PTP activity was assayed using p-nitrophenyl phosphate (pNPP) as a substrate in DMG buffer (50 mM DMG, pH 7.0, 1 mM EDTA, 150 mM NaCl, 2 mM DTT, 0.1 mg/mL BSA) at 25 degrees C. The assays were performed in 96-well plates. Normally, to determine the IC50 values, the reaction was initiated by the addition of enzyme (final concentration of 10 nM) to a reaction mixture (0.2 mL) containing 2 mM (Km for the substrate) pNPP with various concentrations of inhibitors. The reaction rate was measured using a Spectra Max Plus 384 Microplate Spectrophotometer (Molecular Devices). For compound 10, the final TC-PTP concentration was 0.04 nM. The reactions were incubated at room temperature for 30 min and quenched with 5N NaOH. The absorbance at 405 nm was read on the SpectraMax Plus 384 Microplate Spectrophotometer. For the reversibility test, the enzyme was incubated with the inhibitor at room temperature for 30 min before pNPP was added to initiate the reaction. The reaction was th,62. Inhibition of recombinant human LMW-PTP isoform 2 expressed in Escherichia coli TB1,63. Inhibition of recombinant human LMW-PTP isoform 1 expressed in Escherichia coli TB1,64. SAR confirmation of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay, set 2,65. SAR confirmation of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay,66. Dose response confirmation of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay,67. Cytotoxicity against human MCF7 cells after 48 hrs by acid phosphatase method,68. Cytotoxicity against human HepG2 cells after 48 hrs by acid phosphatase method,69. Inhibition of Saccharomyces cerevisiae low molecular weight Protein-tyrosine phosphatase Ltp1,70. Inhibition of bovine low molecular weight PTP expressed in Escherichia coli BL21(D3) cells,71. Competitive inhibition of mouse LMW-PTP expressed in Escherichia coli using pNPP substrate by Dixon plot,72. Inhibition of bovine heart acid phosphatase,73. Inhibition of human purple acid phosphatase,74. Inhibition of pig purple acid phosphatase at pH 4.9,75. Inhibition of pig purple acid phosphatase at pH 3.3,76. Inhibition of human recombinant purple acid phosphatase at pH 4.9,77. Inhibition of human recombinant purple acid phosphatase at pH 3.3,78. Inhibition of bovine kidney LMW-PTPase using phosphotyrosine substrate,79. Antitrypanosomal activity against Trypanosoma brucei brucei MiTat 1.2 strain 427 bloodstream by acid phosphatase method,80. Antiresorptive activity in mouse RAW264.7 cells assessed as inhibition of tartrate-resistant acid phosphatase activity,81. Antiresorptive activity against 1,25-dihydroxyvitamin D3-stimulated osteoclast formation in Swiss Webster mouse bone marrow cells assessed as reduction of tartrate-resistant acid phosphatase activity after 7 days,82. Antiproliferative activity against human HT144 cells after 5 days by acid phosphatase assay,83. Antiproliferative activity against P-gp expressing human DLKP-A cells after 5 days by acid phosphatase assay,84. Antiproliferative activity against MRP1-expressing human DLKP cells after 5 days by acid phosphatase assay,85. Inhibition of Saccharomyces cerevisiae Ltp1,86. Leishmanicidal activity against promastigote stage of Leishmania infantum MCAN/ES/92/BCN722 after 48 hrs by acid phosphatase based assay,87. Selectivity Counterscreen Cell Adhesion Assay for Inhibitors of Platelet Integrin alphallb-beta3
ACTIVITYSubstance BioActivity: 7 Active, 5 Activity <= 1 µM, 7 Tested Substance BioActivity: 5 Tested Substance BioActivity: 4 Tested Substance BioActivity: 3 Active, 7 Tested Substance BioActivity: 2 Active, 1 Activity <= 1 µM, 2 Tested Substance BioActivity: 10 Active, 10 Tested Substance BioActivity: 5 Tested Substance BioActivity: 12 Active, 26 Tested Substance BioActivity: 3 Tested Substance BioActivity: 3 Active, 4 Tested Substance BioActivity: 1 Active, 1 Activity <= 1 µM, 1 Tested Substance BioActivity: 8 Active, 7 Activity <= 1 µM, 8 Tested Substance BioActivity: 4 Active, 3 Activity <= 1 µM, 7 Tested Substance BioActivity: 7 Active, 3 Activity <= 1 nM, 7 Activity <= 1 µM, 7 Tested Substance BioActivity: 9 Tested Substance BioActivity: 5 Active, 9 Tested Substance BioActivity: 19 Active, 24 Tested Substance BioActivity: 2 Tested Substance BioActivity: 5 Active, 7 Tested Substance BioActivity: 8 Tested Substance BioActivity: 1 Active, 1 Tested Substance BioActivity: 3 Tested Subs